sakk 08/16: darolutamide maintenance therapy for previously treated patients with mcrpc
Published 2 years ago • 61 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
0:45
treatment sequencing for metastatic castration-resistant prostate cancer
-
1:23
the evolving treatment landscape of mhspc and mcrpc
-
5:12
darolutamide for nmcrpc: results of the aramis trial
-
2:46
aramis: darolutamide in patients with nmcrpc
-
0:20
darolutamide - nubeqa in a nutshell.
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
1:18:00
urowebinar: identification and management of patients with nmcrpc
-
7:50
darolutamide(nubeqa) for non metastatic castration resistant prostate cancer
-
4:56
improving the prognosis for patients with mcrpc
-
2:38
safety outcomes of darolutamide vs apalutamide and enzalutamide in nmcrpc
-
1:41
the role of triplet therapy in men with metastatic castration sensitive prostate cancer
-
21:56
treatments for #prostatecancer bone metastasis | #markscholzmd #alexscholz #pcri
-
12:08
new fda approval: darolutamide for hormone-sensitive disease | mark scholz, md | pcri
-
0:52
dr. lawrence karsh on treatment sequencing in metastatic castration-resistant prostate cancer
-
1:37
cabazitaxel rechallenge in patients with metastatic castration resistant prostate cancer
-
3:12
cabazitaxel (jevtana) for progressive metastatic prostate cancer after taxotere
-
1:29
evaluating the role of sbrt in metastatic castrate-resistant prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
1:52
prostate cancer: quality of life maintained with darolutamide